Transforming growth factor-β activity is potentiated by heparin via dissociation of the transforming growth factor-β/α2-macroglobulin inactive complex

T. A. McCaffrey, D. J. Falcone, Cory Brayton, L. A. Agarwal, F. G P Welt, B. B. Weksler

Research output: Contribution to journalArticle

Abstract

The control of smooth muscle cell (SMC) proliferation is determined by the combined actions of mitogens, such as platelet-derived growth factor, and the opposing action of growth inhibitory agents, such as heparin and transforming growth factor-β (TGF-β). The present studies identify an interaction between heparin and TGF-β in which heparin potentiates the biological action of TGF-β. Using a neutralizing antibody to TGF-β, we observed that the short term antiproliferative effect of heparin depended upon the presence of biologically active TGF-β. This effect was observed in rat and bovine aortic SMC and in CCL64 cells, but not in human saphenous vein SMC. Binding studies demonstrated that the addition of heparin (100 μg/ml) to medium containing 10% plasma-derived serum resulted in a 45% increase in the specific binding of 125I-TGF-β to cells. Likewise, heparin induced a twofold increase in the growth inhibitory action of TGF-β at concentrations of TGF-β near its apparent dissociation constant. Using 125I-labeled TGF-β, we demonstrated that TGF-β complexes with the plasma component α2-macroglobulin, but not with fibronectin. Heparin increases the electrophoretic mobility of TGF-β apparently by freeing TGF-β from its complex with α2-macroglobulin. Dextran sulfate, another highly charged antiproliferative molecule, but not chondroitin sulfate or dermatan sulfate, similarly modified TGF-β's mobility. Relatively high antiproliferative concentrations of heparin (1-100 μg/ml) were required to dissociate the TGF-β/α2-macroglobulin complex. Thus, it appears that the antiproliferative effect of heparin may be partially attributed to its ability to potentiate the biological activity of TGF-β by dissociating it from α2-macroglobulin, which normally renders it inactive. We suggest that heparin-like agents may be important regulators of TGF-β's biological activity.

Original languageEnglish (US)
Pages (from-to)441-448
Number of pages8
JournalJournal of Cell Biology
Volume109
Issue number1
StatePublished - 1989
Externally publishedYes

Fingerprint

Macroglobulins
Transforming Growth Factors
Heparin
Smooth Muscle Myocytes
Dextran Sulfate
Platelet-Derived Growth Factor
Saphenous Vein
Growth
Neutralizing Antibodies

ASJC Scopus subject areas

  • Cell Biology

Cite this

Transforming growth factor-β activity is potentiated by heparin via dissociation of the transforming growth factor-β/α2-macroglobulin inactive complex. / McCaffrey, T. A.; Falcone, D. J.; Brayton, Cory; Agarwal, L. A.; Welt, F. G P; Weksler, B. B.

In: Journal of Cell Biology, Vol. 109, No. 1, 1989, p. 441-448.

Research output: Contribution to journalArticle

McCaffrey, T. A. ; Falcone, D. J. ; Brayton, Cory ; Agarwal, L. A. ; Welt, F. G P ; Weksler, B. B. / Transforming growth factor-β activity is potentiated by heparin via dissociation of the transforming growth factor-β/α2-macroglobulin inactive complex. In: Journal of Cell Biology. 1989 ; Vol. 109, No. 1. pp. 441-448.
@article{ceff8e926ee0407fa29d958a0e3b0e47,
title = "Transforming growth factor-β activity is potentiated by heparin via dissociation of the transforming growth factor-β/α2-macroglobulin inactive complex",
abstract = "The control of smooth muscle cell (SMC) proliferation is determined by the combined actions of mitogens, such as platelet-derived growth factor, and the opposing action of growth inhibitory agents, such as heparin and transforming growth factor-β (TGF-β). The present studies identify an interaction between heparin and TGF-β in which heparin potentiates the biological action of TGF-β. Using a neutralizing antibody to TGF-β, we observed that the short term antiproliferative effect of heparin depended upon the presence of biologically active TGF-β. This effect was observed in rat and bovine aortic SMC and in CCL64 cells, but not in human saphenous vein SMC. Binding studies demonstrated that the addition of heparin (100 μg/ml) to medium containing 10{\%} plasma-derived serum resulted in a 45{\%} increase in the specific binding of 125I-TGF-β to cells. Likewise, heparin induced a twofold increase in the growth inhibitory action of TGF-β at concentrations of TGF-β near its apparent dissociation constant. Using 125I-labeled TGF-β, we demonstrated that TGF-β complexes with the plasma component α2-macroglobulin, but not with fibronectin. Heparin increases the electrophoretic mobility of TGF-β apparently by freeing TGF-β from its complex with α2-macroglobulin. Dextran sulfate, another highly charged antiproliferative molecule, but not chondroitin sulfate or dermatan sulfate, similarly modified TGF-β's mobility. Relatively high antiproliferative concentrations of heparin (1-100 μg/ml) were required to dissociate the TGF-β/α2-macroglobulin complex. Thus, it appears that the antiproliferative effect of heparin may be partially attributed to its ability to potentiate the biological activity of TGF-β by dissociating it from α2-macroglobulin, which normally renders it inactive. We suggest that heparin-like agents may be important regulators of TGF-β's biological activity.",
author = "McCaffrey, {T. A.} and Falcone, {D. J.} and Cory Brayton and Agarwal, {L. A.} and Welt, {F. G P} and Weksler, {B. B.}",
year = "1989",
language = "English (US)",
volume = "109",
pages = "441--448",
journal = "Journal of Cell Biology",
issn = "0021-9525",
publisher = "Rockefeller University Press",
number = "1",

}

TY - JOUR

T1 - Transforming growth factor-β activity is potentiated by heparin via dissociation of the transforming growth factor-β/α2-macroglobulin inactive complex

AU - McCaffrey, T. A.

AU - Falcone, D. J.

AU - Brayton, Cory

AU - Agarwal, L. A.

AU - Welt, F. G P

AU - Weksler, B. B.

PY - 1989

Y1 - 1989

N2 - The control of smooth muscle cell (SMC) proliferation is determined by the combined actions of mitogens, such as platelet-derived growth factor, and the opposing action of growth inhibitory agents, such as heparin and transforming growth factor-β (TGF-β). The present studies identify an interaction between heparin and TGF-β in which heparin potentiates the biological action of TGF-β. Using a neutralizing antibody to TGF-β, we observed that the short term antiproliferative effect of heparin depended upon the presence of biologically active TGF-β. This effect was observed in rat and bovine aortic SMC and in CCL64 cells, but not in human saphenous vein SMC. Binding studies demonstrated that the addition of heparin (100 μg/ml) to medium containing 10% plasma-derived serum resulted in a 45% increase in the specific binding of 125I-TGF-β to cells. Likewise, heparin induced a twofold increase in the growth inhibitory action of TGF-β at concentrations of TGF-β near its apparent dissociation constant. Using 125I-labeled TGF-β, we demonstrated that TGF-β complexes with the plasma component α2-macroglobulin, but not with fibronectin. Heparin increases the electrophoretic mobility of TGF-β apparently by freeing TGF-β from its complex with α2-macroglobulin. Dextran sulfate, another highly charged antiproliferative molecule, but not chondroitin sulfate or dermatan sulfate, similarly modified TGF-β's mobility. Relatively high antiproliferative concentrations of heparin (1-100 μg/ml) were required to dissociate the TGF-β/α2-macroglobulin complex. Thus, it appears that the antiproliferative effect of heparin may be partially attributed to its ability to potentiate the biological activity of TGF-β by dissociating it from α2-macroglobulin, which normally renders it inactive. We suggest that heparin-like agents may be important regulators of TGF-β's biological activity.

AB - The control of smooth muscle cell (SMC) proliferation is determined by the combined actions of mitogens, such as platelet-derived growth factor, and the opposing action of growth inhibitory agents, such as heparin and transforming growth factor-β (TGF-β). The present studies identify an interaction between heparin and TGF-β in which heparin potentiates the biological action of TGF-β. Using a neutralizing antibody to TGF-β, we observed that the short term antiproliferative effect of heparin depended upon the presence of biologically active TGF-β. This effect was observed in rat and bovine aortic SMC and in CCL64 cells, but not in human saphenous vein SMC. Binding studies demonstrated that the addition of heparin (100 μg/ml) to medium containing 10% plasma-derived serum resulted in a 45% increase in the specific binding of 125I-TGF-β to cells. Likewise, heparin induced a twofold increase in the growth inhibitory action of TGF-β at concentrations of TGF-β near its apparent dissociation constant. Using 125I-labeled TGF-β, we demonstrated that TGF-β complexes with the plasma component α2-macroglobulin, but not with fibronectin. Heparin increases the electrophoretic mobility of TGF-β apparently by freeing TGF-β from its complex with α2-macroglobulin. Dextran sulfate, another highly charged antiproliferative molecule, but not chondroitin sulfate or dermatan sulfate, similarly modified TGF-β's mobility. Relatively high antiproliferative concentrations of heparin (1-100 μg/ml) were required to dissociate the TGF-β/α2-macroglobulin complex. Thus, it appears that the antiproliferative effect of heparin may be partially attributed to its ability to potentiate the biological activity of TGF-β by dissociating it from α2-macroglobulin, which normally renders it inactive. We suggest that heparin-like agents may be important regulators of TGF-β's biological activity.

UR - http://www.scopus.com/inward/record.url?scp=0024356385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024356385&partnerID=8YFLogxK

M3 - Article

C2 - 2473082

AN - SCOPUS:0024356385

VL - 109

SP - 441

EP - 448

JO - Journal of Cell Biology

JF - Journal of Cell Biology

SN - 0021-9525

IS - 1

ER -